Analyzing...
Loading company...
Nothing flagged for monitoring
No significant strengths identified from available data
“Operates in Pharmaceuticals — Formulations & API.”
₹3,012 Cr revenue.
COGS 37.6%, employees 21.6%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 0.5%▼ | 10.5% |
| ROCE | 3.5%▼ | 13.8% |
| Net Margin | 0.7%▼ | 8.7% |
| EBITDA Margin | 14.4%▼ | 16.0% |
| Debt To Equity | 0.51x▲ | 0.21x |
| Rev Growth 3yr | -1.8%▼ | 5.8% |
| EPS Growth 3yr | -44.5%▼ | 3.6% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,151 Cr +4.6% | ₹3,012 Cr +7.6% | ₹2,798 Cr +5.5% | ₹2,651 Cr -17.9% | ₹3,230 Cr +19.3% | ₹2,708 Cr -4.8% | ₹2,844 Cr -31.6% | ₹4,158 Cr |
| Other Income | ₹81 Cr +30.6% | ₹62 Cr -25.3% | ₹83 Cr -32.0% | ₹122 Cr +510.0% | ₹20 Cr -84.9% | ₹132 Cr +240.8% | ₹39 Cr +84.6% | ₹21 Cr |
| Total Income | ₹3,232 Cr +5.1% | ₹3,074 Cr +6.7% | ₹2,881 Cr +3.9% | ₹2,773 Cr -14.7% | ₹3,250 Cr +14.4% | ₹2,841 Cr -1.5% | ₹2,883 Cr -31.0% | ₹4,179 Cr |
| COGS | ₹1,074 Cr -5.1% | ₹1,132 Cr -2.8% | ₹1,165 Cr +4.9% | ₹1,111 Cr -12.3% | ₹1,267 Cr +11.6% | ₹1,135 Cr -5.6% | ₹1,203 Cr -33.7% | ₹1,815 Cr |
| ₹3,098 Cr +0.3% | ₹3,090 Cr -6.0% | ₹3,287 Cr +5.9% | ₹3,103 Cr -10.8% | ₹3,478 Cr +6.5% | ₹3,266 Cr +1.3% | ₹3,225 Cr -28.0% | ₹4,480 Cr | |
| Profit Before Tax | ₹27 Cr ↑ Recovery | (₹16 Cr) +96.2% | (₹420 Cr) +32.7% | (₹624 Cr) -51.8% | (₹411 Cr) +27.7% | (₹568 Cr) -66.2% | (₹342 Cr) -13.9% | (₹300 Cr) |
| Exceptional Items | (₹107 Cr) | ₹0.00 Cr +100.0% | (₹14 Cr) +95.2% | (₹294 Cr) -60.7% | (₹183 Cr) -28.4% | (₹142 Cr) | ₹0.00 Cr | ₹0.00 Cr |
| ₹37 Cr -9.8% | ₹41 Cr -21.2% | ₹52 Cr ↑ Recovery | (₹3 Cr) +97.7% | (₹132 Cr) +51.4% | (₹272 Cr) -33.1% | (₹204 Cr) -144.0% | (₹84 Cr) | |
| Net Profit | (₹10 Cr) +82.5% | (₹57 Cr) +87.9% | (₹472 Cr) +24.0% | (₹621 Cr) -122.6% | (₹279 Cr) ↓ Decline | ₹689 Cr ↑ Recovery | (₹43 Cr) +80.0% | (₹217 Cr) |
| Profit (Owners) | ₹22 Cr ↑ Recovery | (₹47 Cr) +89.8% | (₹463 Cr) +17.2% | (₹559 Cr) -129.1% | (₹244 Cr) ↓ Decline | ₹686 Cr ↑ Recovery | (₹69 Cr) +64.4% | (₹195 Cr) |
| Minority Interest | (₹32 Cr) -220.0% | (₹10 Cr) -11.1% | (₹9 Cr) +85.5% | (₹62 Cr) -77.1% | (₹35 Cr) ↓ Decline | ₹3 Cr -90.2% | ₹26 Cr ↑ Recovery | (₹22 Cr) |
| Other Comprehensive Income | ₹325 Cr +357.7% | ₹71 Cr | ₹6 Cr -92.3% | ₹78 Cr ↑ Recovery | (₹27 Cr) -578.4% | (₹4 Cr) ↓ Decline | ₹101 Cr | ₹9 Cr |
| EPS | ₹1.35 | (₹2.89) | (₹30.18) | (₹38.80) | (₹16.94) | ₹47.64 | (₹4.81) | (₹13.52) |
| Diluted Shares | ₹16 Cr | ₹16 Cr | ₹15 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations andDisclosure Requirements) Regulations, 2015, as amended and in continuation to our letter bearing referen...
Wockhardt Limited has informed the Exchange about Investor Presentation
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release titled, Indian drug regulator grants marketing authorization to Wockhardt's breakthrough antibiotic, ZAYNICH® (Zide...
Wockhardt Limited has informed the Exchange about Credit Rating
Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on theAudited Financial Results (Standalone and Consolidated) for the quarter and the financial yearended 31st ...
Pursuant to Regulation 30 and 33 of Listing Regulations read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing R...
Pursuant to Regulation 30 and 33 of Listing Regulations read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing R...
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release -"Wockhardt's Zaynich® (Zidebactam/Cefepime) Receives Favourable Recommendation from CDSCO's Subject Expert Committ...
Wockhardt Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Pursuant to Regulation 30 read with Schedule III part A para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the newspaperadvertisement...
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, we wish ...
Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI (Issue of Capital and Disclosure Requirements) Regul...
Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st De...
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter beari...
In terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Re...
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.